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Abstract
Background: Krill powder is rich in bioactive ingredients such as eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA), phospholipids, protein and astaxanthin. Containing dominantly EPA, it is considered to be effective in
lowering lipids, foremost serum triglycerides and LDL cholesterol. Krill-derived protein hydrolysates/peptides may
have positive effect on blood pressure and astaxanthin has anti-oxidative and anti-inflammatory properties. Thus,
krill powder has a lot of potential in improving lipid and metabolic profile and reinforcing the activity of the
antioxidant system. However, randomized clinical trials on krill powder are scarce and systematic data of krill meal
on human safety is limited. Some of the earlier studies have reported several, non-serious adverse events, mostly
related to gastrointestinal tract, but systematic sufficiently powered study on safety is lacking. The aim of this study
was to collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by
measuring the risk factors for cardiovascular disease.
Methods: The study was a randomised, double-blinded, placebo-controlled intervention study with 35 overweight
subjects with mildly or moderately elevated blood pressure, who took 4 g krill oil powder or 4 g of placebo during
an 8-week follow-up period. The study consisted of a pre-screening, screening, day 0 baseline (randomization visit)
and three follow-up visits on days 14, 28 and 56. The reported adverse events in the groups were compared as
primary endpoint and haematological safety parameters and changes in systolic and diastolic pressure and blood
total and lipoprotein lipids were measured as secondary end points.
Results: There were in total 80 reported adverse events during the follow-up; 50 in placebo and 30 in krill powder
group. Gastrointestinal symptoms (flatulence, heartburn and diarrhea) were the most commonly reported among
those probably related to the test products. No serious adverse events were reported. The mean value of all
measured hematology variables remained within the reference values in all study subject and no significant
changes were observed in blood pressure or lipid values.
Conclusions: The results seem to indicate that using krill powder as a source for EPA and DHA is safe in
therapeutic dose and the risk of adverse events, let alone serious ones, is low.
Trial registration: ClinicalTrials.gov, NCT03112083, retrospectively registered.
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Background
Krill powder is reddish powder produced from antarctic
krill (Euphasia superba). It is rich in multiple bioactive
ingredients such as EPA and DHA, phospholipids, pro-
tein and astaxanthin. Krill oil has been studied repeat-
edly but the studies on krill meal and its safe use in
humans are few.
Krill oil contains dominantly EPA compared to fish
oils containing higher proportion of DHA [1]. The effect
of long-chain n-3 fatty acid on serum LDL cholesterol is
slightly controversial, since the effect has been found to
be neutral or even adverse with some formulations or
high doses and in some studies. In general, treatment
with EPA + DHA appears to lower patient triglycerides
effectively, but in patients with very high triglyceride
levels, use of EPA + DHA may raise low-density lipopro-
tein cholesterol levels, whereas EPA alone may not do
that. It is well established that triglyceride concentra-
tions are linked to other markers of metabolic syndrome
such as insulin [1–3]. The effect of krill powder on
non-lipid metabolic markers such as blood glucose is
much more controversial and human studies have been
mostly made with krill oil, only one with krill meal so
far [4–8].
EPA and DHA are known to increase hemostasis via
their inhibitory effects on platelet function, without in-
creasing bleeding as such [1, 9] . EPA and DHA also
suppress the production of arachidonic-acid-derived ei-
cosanoids and EPA is a substrate for the synthesis of an
alternative family of eicosanoids. Thus, dietary fats
which are rich in n-3 PUFAs have the potential to alter
cytokine production and modulate inflammation [5, 6].
In addition, astaxanthin is a carotenoid that contributes
to krill’s anti-oxidative and anti-inflammatory properties
[7]. However so far, the in vivo data in humans with krill
meal derived astaxanthin are also scarce [10, 11].
Recently more and more interest has also been paid to
the cardio-protective activity of proteins or peptides de-
rived from marine sources [12]. Marine proteins and
peptides could have a lowering effect on blood pressure
[11, 13, 14]. Krill powder is relative high in protein
(55%) and therefore it is interesting to evaluate its effect
on blood pressure and other vascular elasticity markers,
especially since current human data on antihypertensive
activity of krill-derived protein hydrolysates/peptides is
lacking also in safety terms [14–16].
In summary, krill powder with its various bioactive
components has a lot of potential in improving lipid
profile, suppressing lipid peroxidation, and reinforcing
the activity of the antioxidant system and thus it reduces
vascular wall inflammation, stabilizes membrane proper-
ties or increases vascular elasticity. These all together
could prevent progression of atherosclerosis. However,
as randomized clinical trials on krill powder are still
scarce [7, 17], systematic data on human safety is limited
sofar. Some of the earlier studies have reported several,
non-serious adverse events, mostly related to gastro-
intestinal tract [7, 17], but no systematic study focusing
on safety has been done yet. Consequently, there was a
clear need to systematically collect data on its safety and
tolerability in humans. Simultaneously, we aimed to gain
efficacy data on krill powder by measuring various risk
factors for cardiovascular disease.
Study objectives
Primary objective
The primary objective of the study was to compare the
amount and the type of adverse events during 8-week
follow-up after ingestion of krill powder preparation in
comparison to ingestion of respective amount of placebo
in overweight study subjects with mildly or moderately
elevated blood pressure.
Secondary objectives
In addition to adverse effect, the aim was also to com-
pare safety parameters, i.e. blood count, creatinine,
gamma glutamyl transferase, aspartate aminotransferase
(AST) and (alanine aminotransferase) ALT and to meas-
ure changes in selective efficacy parameters such as sys-
tolic and diastolic blood pressure as well as blood total
and lipoprotein lipids during the whole 8-week
follow-up period of the study.
Subjects and methods
Study subjects
Study subjects were recruited through advertisements in
local newspapers, public notice boards and research sites
from Tampere and Oulu area (in Central and Northern
Finland). Inclusion criteria were: 1) age 18–65 years, 2)
overweight female or male (BMI between 25 and 30 kg/
m2), 3) mildly or moderately elevated blood pressure
(systolic 140–159/ diastolic 90–99mmHg) and 4) signed
written informed consent. The exclusion criteria were:
1) medication potential to affect serum lipids (lipid-low-
ering drugs), 2) familial hypercholesterolemia, marked
combined hyperlipidemia, condition that would impair
fat absorption (e.g. chronic pancreatitis, pancreatic lipase
deficiency syndrome), 3) any untreated medical condi-
tion affecting absorption of fat, 4) type 1 and 2 diabetes,
5) cancer or other malignant disease within the past 5
years, 6) periodical hormone replacement therapy, 7)
high intake of oily fish (> 2 times per week as a principal
meal) (i.e. salmon, herring, sardines, mackerel, vendace),
8) smoking, 9) alcohol consumption > 15 doses per
week, 10) pregnant, lactating or wish to become preg-
nant, 11) hypersensitivity to fish or any of the components
of the test products, 12) regular use (> 3 times per week)
of n-3 or other fatty acid supplements, plant sterols or
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fiber supplements 4 weeks before randomization, 13) lack
of suitability for participation in the trial, for any medical
reason, as judged by the PI.
Subjects would have been withdrawn from the study if
pregnancy or any other diagnosed medical condition or
treatment stated above as the exclusion criteria had
taken place during the study. All study subjects had a
right to discontinue the study at any point, if they
wanted to stop taking part in the study.
Study design and procedures
The study was a randomised, double-blinded,
placebo-controlled intervention study with overweight
subjects with mildly or moderately elevated blood pres-
sure. Two-arm parallel design was followed in the study.
Study was conducted at two study sites in Central (Tam-
pere) and Northern Finland (Oulu). In total 35 subjects
were randomised according to randomisation list to two
groups (krill powder or placebo) in a balanced manner
(1:1), separately for both gender and site. Concealed allo-
cation was used to keep both subjects and staff blinded.
The study consisted of a pre-screening, a screening visit
7 to 14 days before randomization, Day 0 baseline
(Randomization visit) and 8-week intervention with
safety and tolerance follow-up period with three visits
on Day 14, Day 28 and Day 56.
A total of 6 study visits were included. At pre-screening
visit the study subjects were requested to sign informed
consent form. A structured interview on demographics
(age, sex, ethnicity), previous and current diseases, current
medication, alcohol and tobacco consumption and use of
dietary supplements (especially fish oil and other n-3 FA
supplements, plant sterols and cholesterol lowering fibre
supplements (guar gum, glucomannan, oat fibre etc.) and
use of fish foods was carried out at the screening visit and
replicated at the day 56 visit.
At baseline visit primary (number of adverse events)
and all secondary and optional endpoint measurements
were taken. At day 14, 28 and 56, the study diaries were
checked and blood pressure was measured. During day
28 and 56 visits safety laboratory measurements and
blood lipoprotein measurements were also taken. At day
56 the test product accountability was performed to
check the compliance during the follow-up.
Test products and background diet
Study included one test product: krill powder derived
from antarctic krill (Euphausia superba) (Rimfrost Pris-
tine®, Rimfrost AS, PO box 234, 6099 Fosnavåg, Norway)
and placebo product and both were given in capsule
form, 4 capsules in the morning and 4 in the evening
providing 4 g dose daily. Maize starch (Pharmatech AS,
Rolvsøy, Norway) acted as an inert placebo and was
filled in the parallel capsules as the krill powder. Same
excipients and masking flavour were used in krill and
placebo capsules. Composition for active product is
given in the Table 1. Study products were delivered to
study subjects at Day 0, Day 14 and Day 28 visits equal-
ing the amounts needed for each follow-up period with
extra capsules for 1 week. Study personnel recorded the
amounts of capsules given for each study subject and
the amount returned (also empty blisters) at each visit.
Nutritional counselling regarding the consumption of
fish, omega-3 and -6 fatty acids, food supplements and
investigational product for the duration of the study
were given for the study subjects at the screening visit
by a study nurse or registered dietitian and compliance
was followed throughout the study. The subjects were
advised to keep their medication, lifestyle, background
diet and body weight constant during the study and de-
viation were recorded into the diary.
Primary endpoint: Adverse event (AE) follow-up
As a primary endpoint of the study, the total number of
reported adverse events were compared in the study
subject groups taking 8 capsules (4 g) krill oil powder or
8 capsules (4 g) of placebo for the 8-week follow-up
period. Any unfavourable and unintended sign, symptom
or medical complaint and worsening of a pre-existing
condition was regarded as AE. Study subjects kept diary
for the whole duration of the study and were requested
to write down all unfavourable symptoms and medical
complaints not existing at baseline or significantly wors-
ened from baseline situation. Completeness of diaries
was checked at each study visit. All reported adverse
events were recorded, coded and analysed carefully to
determine severity, possible relation to study products,
onset and outcome of the event.
Anthropometric and blood pressure measurements
Body weight was measured with the same calibrated,
digital scale at screening visit and at Day 56 follow-up
visit while the subjects were wearing light indoor cloth-
ing and no shoes and recorded with 0.1 kg precision.
Table 1 Composition of krill powder Rimfrost Pristine®
Nutrient Amount Unit
Moisture max 6 %
Fat max 25 %
Protein (N*6.25) min 55 %
Ash max 10 %
Phopsholipids min 10 %
EPA (20:5 n-3) as FFA min 2.5 g/100 g
DHA C22:6 n-3 as FFA min 1.5 g/100 g
Total n-3 as FFA min 5.0 g/100 g
Esterified Astaxanthin min 40 mg/kg
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The weight measurement was replicated once and the
mean of two measurements was used in the statistical
analysis. Body mass index was calculated with the fol-
lowing formula: body mass (kg) / (height (m))2. Height
was measured at screening visit with the subject stand-
ing straight, hands on the side, shoulders relaxed and
heels together in so called Frankfurt position and result
was recorded to the nearest 0.5 cm.
Blood pressure (BP) was measured at all visits using
automatic blood pressure measuring device that was vali-
dated according to standardized protocols and calibrated
periodically. Before BP measurements, study subjects were
advised to avoid heavy physical exercise, smoking and
consumption of caffeine rich drinks. BP measurements
were conducted in a quiet room and subjects were seated
comfortably, with back supported, legs un-crossed, and
subjects were allowed to rest 3–5min, cuff assembled, be-
fore starting the BP measurement. Blood pressure was
measured from the upper arm, supported at the hearth
level. Proper size cuff was placed to the upper arm so that
middle part of the bladder was on the brachial vein. Three
BP measurements spaced 1–2min apart were taken and
recorded with 1mmHg accuracy. In case first two mea-
sures differed significantly (over 10mmHg), additional
measurements were taken. Average of last two measure-
ments were used in the analysis. At the first visit measure-
ments were taken repeatedly from both arms and if the
measures differed significantly, in the follow-up measure-
ments the arm giving higher values was used.
Laboratory measurements
Study subjects were instructed to follow normal fasting pro-
cedures before the study visits if blood samples were taken,
i.e. to be without food and drink (except small amount of
water) 10–12 h before sampling and to avoid alcohol con-
sumption also the day before laboratory tests. Routine
clinical chemistry and hematology (blood count, serum
thyrotropin, serum creatinine, plasma gamma-glutamyl
transferase, blood glucose, AST, ALT) were analyzed at Day
0 and 56 with standardized clinical chemistry and
hematology methods at Fimlab or Medix Laboratories.
Plasma total and lipoprotein lipids were analysed using
commercial methods and reagents; total triglycerides and
total cholesterol with enzymatic, colorimetric test and LDL-
and HDL-cholesterol concentrations with homogenous
enzymatic colorimetric method at Fimlab or Medix Labora-
tories (Cobas 6000 analyzer (c501 module), Roche Diagnos-
tics, Germany or ADVIA 1800 System, Siemens Healthcare
Inc., NY USA).
Statistical method
The primary variable, number of reported adverse events
in the study groups was compared descriptively and
using a Poisson regression model suitable for analysing
count data. Safety laboratory and metabolic variables be-
tween the study groups were compared using an analysis
of covariance models (ANCOVA) adjusting for baseline
values. Significance level was set to p < 0.05.
Results
A total of 35 subjects signed informed consent and
were randomized according to the randomization list to
two groups (krill powder or placebo). Out of the study
subjects 18 were male and 17 female and the mean age
was 55.4 ± 8.6 years. All participants were Caucasian
and their mean blood pressure at the screening was
140.0 ± 8.9 /87.6 ± 7.6 mmHg. The mean BMI at the
screening was 28.7 ± 1.3 for the krill powder group and
27.3 ± 1.3 for the placebo group, and 28.9 ± 1.4 and
27.7 ± 1.4 at day 56 subsequently. Respective values at
baseline are provided in the Table 2.
Safety
Reported adverse events were coded according system
organ class following adapted ICD-10 main classes. All
safety parameters were measured at screening, base line,
Table 2 Baseline characteristics of the study subjects
ALL n = 35 Krill Powder
Value n = 18
Placebo
Value n = 17
Gender (n) Female 17 8 9
Male 18 10 8
Race (n) Caucasian 35 18 17
Age (yrs) N 35 18 17
Mean 55.4 55.3 55.5
SD 8.6 8.4 9.0
Min 33 38 33
Median 57.0 57.5 57.0
Max 65 65 65
BMI (kg/m2) Mean 28.0 28.7 27.3
SD 1.3 1.3 1.3
Systolic blood
pressure (mmHg)
Mean 138.7 141.8 135.4
SD 8.5 8.7 7.2
Diastolic blood
pressure (mmHg)
Mean 87.2 88.6 85.6
SD 6.9 7.7 5.8
Total cholesterol
(mmol/l)
Mean 5.79 5.78 5.79
SD 0.89 0.80 1.00
LDL cholesterol
(mmol/l)
Mean 3.92 3.98 3.86
SD 0.92 0.94 0.92
HDL cholesterol
(mmol/l)
Mean 1.56 1.49 1.63
SD 0.48 0.58 0.34
Triglycerides
(mmol/l)
Mean 1.30 1.31 1.29
SD 0.54 0.49 0.61
BMI body mass index, HDL high density lipoprotein, LDL low
density lipoprotein
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day 28 and day 56 and all adverse events reported by the
subjects in their study diaries since the last visit were
collected at day 14, 28 and 56.
Adverse events in main organ classes
There were in total 80 reported AEs during the 56-day
follow-up in 35 subjects (Table 3). Out of those reported
50 were in placebo group and 30 in krill powder group
respectively. The most common AEs reported were
gastrointestinal, respiratory (including common cold),
musculoskeletal (including injuries) and nervous system
(including headache). Out of the 80 reported 12 were
classified to be possibly related to the study products
and only one probably (heartburn in the krill powder
group) and none of the AEs were classified to be defin-
itely related to the study products. Gastrointestinal
symptoms such as flatulence, heartburn and diarrhea,
were the most commonly reported among those possibly
related to the test products. No serious adverse events
were reported during the study.
Hematology and clinical chemistry variables
The mean value of all measured hematology variables
remained within the reference values in all study subject
both in placebo and treatment group and there were no
marked differences between the groups in hematology
variables during the intervention. There were no major
differences between the groups or in comparison to the
baseline readings in the values describing liver and kid-
ney function (Table 4). Serum creatinine (S-Krea) and
serum enzyme glutamyl transferase (S-GT) values
remained well within the reference values throughout
the study. AST remained unchanged at group level, but
there was a clear baseline difference (attributed mainly
to one outlier) between the groups which slightly dimin-
ished during the intervention. ALT value increased
markedly in placebo group and this change was attrib-
uted mainly to one subject having markedly higher ALT
and AST values at day 56 visit.
No significant changes were observed in any of the
other measured hematology and clinical chemistry
values during the whole intervention in either of the
groups (Table 5).
Other results
In addition to safety parameters, LDL, HDL and total
cholesterol as well as triglyceride values were also mea-
sured in all study subjects at baseline, 28 and 56 days
and blood pressure at baseline, 14, 28 and 56 days, as
these were considered interesting from the efficacy point
of view.
LDL, HDL, total cholesterol and triglycerides
No significant change was observed in LDL, total choles-
terol or triglyceride values in either of the groups during
the intervention, p-values for within change were 0.9114,
0.7129 and 0.6410 in the placebo group and 0.8190,
0.8221 and 0.1818 in the krill powder group respectively.
However, a significant increase was found in the HDL
values in the placebo group at the end of the
intervention (p = 0.0231) but not in the krill powder
group (p = 0.7053). No significant difference was ob-
served in any of the values at any of the timepoints
when comparing the two groups to each other. Mean
LDL values (mmol/L) at the baseline measurement were
3.98 ± 0.94 for krill powder group and 3.86 ± 0.93 for
placebo group and at the end of the intervention at day
56 3.95 ± 0.88 and 3.85 ± 0.86, mean HDL (mmol/L) as
1.49 ± 0.58 and 1.63 ± 0.34 compared to 1.48 ± 0.50 and
1.72 ± 0.43 at the end and mean triglycerides (mmol/L)
1.31 ± 0.49 and 1.29 ± 0.61 compared to 1.45 ± 0.72 and
1.24 ± 0.44 at the end of the intervention.
Blood pressure
No consistent change in either the diastolic or the sys-
tolic pressure was observed in either of the groups dur-
ing the intervention (Figs. 1 and 2). No statistically
significant change was observed in either of the groups
Table 3 Adverse events by adapted ICD10 main class, number of subjects (N) and event count (F) in all study subjects during the
whole intervention period
Classified Event All Krill Powder Placebo
F N % F N % F N %
Totala 80 26 74.3 30 10 55.6 50 16 94.1
Gastrointestinal 23 13 37.1 11 5 27.8 12 8 47.1
Mental, behavioral 2 2 5.7 – – – 2 2 11.8
Musculosceletal (inc. injuries) 15 9 25.7 4 3 16.7 11 6 35.3
Nervous system (inc. headache) 14 7 20.0 8 3 16.7 6 4 23.5
Other (inc. unclassified abnormal lab values) 6 5 14.3 – – – 6 5 29.4
Respiratory (inc. common cold) 20 15 42.9 7 5 27.8 13 10 58.8
aRate ratio (active/placebo) of adverse event counts (poisson regression model), contrast estimate results: mean (0.5667; Confidence limits 0.3604; 0.8911)
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for diastolic pressure during the intervention (p = 0.09
for krill powder and 0.80 for placebo), but there was a
significant decrease in systolic pressure at the end of the
intervention in krill powder group (p = 0.0057). However,
no significant difference was observed when comparing
the two groups to each other (p = 0.12).
Discussion
The results show that krill powder is well tolerated and
safe to use in therapeutic doses. The number of reported
adverse events was higher in the placebo group than in
the krill powder group and only one of the reported AEs
in the krill powder group was considered to be definitely
Table 4 Liver and kidney function values at screening, baseline,
day 28 and day 56
Parameter Krill powder,
mean value
(n = 18)
Krill
powder,
SD
Placebo,
mean value
(n = 17)
Placebo,
SD
P-value
(Krill powder
vs. Placebo)
S-ALT (U/I)
SCR 25.4 12.0 30.5 14.1
BAS 25.8 12.0 32.6 20.9
D28 27.5 14.9 30.0 18.3 0.1231
D56 27.1 9.0 41.0 33.5 0.2297
S-AST (U/I)
SCR 23.6 4.5 26.4 5.5
BAS 24.9 5.8 36.1 38.3
D28 27.4 12.5 34.3 37.8 0.2356
D56 24.3 4.8 34.9 23.9 0.1521
S-GT (U/I)
SCR 26.0 11.1 29.1 13.7
BAS 27.0 14.3 28.5 13.7
D28 26.2 10.8 28.1 12.5 0.4191
D56 27.7 11.3 30.1 14.2 0.4160
S-Krea (μmol/L)
SCR 73.9 10.6 75.8 12.4
BAS 73.5 9.5 75.5 13.6
D28 72.2 12.0 74.6 12.3 0.7920
D56 72.5 10.9 74.7 14.9 0.9478
SCR screening, BAS baseline, S- ALT serum alanine aminotransferase, S-AST
serum aspartate transaminase, S-GT serum gamma glutamyl transferase, S-Krea
serum creatinine
Table 5 Hematological values at screening, baseline, day 28
and day 56
Parameter
(unit)
Krill powder,
mean value
(n = 18)
Krill
powder,
SD
Placebo,
mean value
(n = 17)
Placebo,
SD
P-value
(Krill powder
vs. Placebo)
B-Hb (g/L)
SCR 147.8 11.2 146.1 8.4
BAS 146.2 10.2 144.2 8.1
D28 147.4 11.2 145.1 8.7 0.8074
D56 145.6 11.6 143.8 7.3 0.9517
B-HCT (%)
SCR 44.3 2.9 43.9 2.1
BAS 43.4 2.8 42.8 2.5
D28 44.5 2.4 44.3 2.2 0.7642
D56 44.1 3.2 43.1 2.3 0.3581
E-MCV (fL)
SCR 90.1 4.7 88.5 4.6
BAS 89.5 4.7 87.2 4.2
D28 90.8 4.7 89.6 5.4 0.2584
D56 90.8 4.9 88.7 5.2 0.9008
E-MCH (pg)
SCR 30.1 2.3 29.5 1.8
BAS 30.2 2.1 29.5 1.9
D28 30.1 2.4 29.5 2.0 0.6181
D56 30.1 2.2 29.7 2.0 0.1709
SCR screening, BAS baseline, B-Hb bood hemoglobin, B-HCT blood hematocrit,
E-MCV erythrocyte mean corpuscular volume, E-MCH mean
corpuscular hemoglobin
Fig. 1 Mean diastolic blood pressure (+/-SD) during the intervention in all study subjects (n= 35), krill powder group (n= 17) and placebo group (n= 18)
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related to the treatment. None of the AEs in either of
the groups were severe. There were no significant
changes in the hematological or clinical chemistry values
either. There was sporadic deviation in liver values (ALT
and AST) at one timepoint, but these elevated AST and
ALT values were considered occasional findings as during
other visits they remained within reference values or
values were not replicated in retest (AST). This is also in
line with secondary results gained from the few previously
done clinical studies with krill oil, where no significant
changes in hematological values nor any notable adverse
events were reported during the treatment [17, 18].
Somewhat surprisingly, no significant difference was
noted in any of the lipid values during the intervention
between the groups. Previous studies with krill oil have
indicated that when used in similar or even lower doses,
positive changes in lipid values can be achieved. The
other possible explanation could also be the differences
between the pharmacokinetic profiles and weaker bio-
availability of krill oil used in those studies and krill
powder used in this study. In a study by Berge et al., sig-
nificant reduction of serum triglycerides was noted with-
out any change in LDL values [18]. Also, in a study by
the same group [17], a significant change was noticed
after 12 and 24 weeks of administration 4 g of krill pow-
der to overweight subjects. However, it is quite well
established that doses 0.5-5 g/day of EPA and DHA does
not necessary reduce LDL cholesterol in normolipide-
mic, but triglycerides are reduced in subjects with ele-
vated triglyceride concentrations [19–21] with krill oil.
In case of other study by Berge et al. [17], performed
with a similar dose of krill powder, the longer duration
of intervention might explain why in that study signifi-
cant differences were found. There were a couple of out-
liers in the Krill group whose triglycerides increased
markedly and this could partly explain the increase in
the variation during our trial. Thus, no consistent
lowering trend for triglycerides could be seen. Another
reason could be that the total dose of n-3 fatty acids
gained via krill powder was simply too low (240 mg) in
this case to generate reduction in serum triglycerides or
the duration of the treatment was too short. Previous
studies have shown that 2–4 g /day of EPA and DHA are
needed to gain hypolipidemic effect in normolipidemic
person [19].
The effects of krill powder on blood pressure in this
study were inconclusive. Contrary to previous studies done
with marine peptides or lipids on blood pressure, there
was no significant change in diastolic pressure [8, 13].
These findings may be due to the high level of intrasubject
variability of the blood pressure values during the
follow-up period. However, krill powder seemed to have a
lowering effect on systolic pressure that was noted at Day
14, 28 and 56 as statistically significant change when com-
paring krill powder to the baseline. However, blood pres-
sure reduced also in Placebo group (at 28 day) and thus no
significant difference could be found, when comparing krill
powder group to placebo group. These results might indi-
cate, that krill powder has a lowering effect on at least sys-
tolic blood pressure, but it cannot be ruled out that
reduction was related to accommodation to blood pres-
sure measurement via replicated measurements. Study
was sufficiently powered to detect differences in AE
reporting, number of observations were in agreement with
initial power calculation even if the sample size remained
smaller than planned. However, study was not sufficiently
powered to see mild effects in metabolic parameters.
Therefore, it would be interesting to confirm the effect of
krill powder on blood pressure with a larger population to
see if the lowering effect would be consistent and statisti-
cally significant, and to test different dosages of krill pow-
der, as in some previous studies it has been noted that the
lowering effect of marine peptides and lipids on blood
pressure may be dose dependent [13].
Fig. 2 Mean systolic blood pressure (+/-SD) during the intervention in all study subjects (n= 35), krill powder group (n= 17) and placebo group (n= 18)
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Conclusions
According to the results collected from the diaries of the
participants, numerically more adverse events were re-
ported in the placebo than in the krill powder group,
but no serious adverse events were reported during the
study in either of the groups. Mild gastrointestinal
symptoms such as flatulence and heartburn were the
most common class of symptoms possibly attributed to
the test product use. There were no differences in mea-
sured haematology variables between the groups and
liver and kidney enzymes remained stable except few oc-
casional high values of AST and ALT detected both at
baseline, that were occasional findings since during
other visits values remained within reference values or
values were not replicated in retest. Somewhat surpris-
ingly, no significant difference was seen in the blood
pressure or lipid values at the end of the intervention
between the groups despite of the slight the tendency
for reduction in systolic blood pressure with krill pow-
der. These results seem to indicate that using krill pow-
der as a source for EPA and DHA is safe in therapeutic
dose and the risk of adverse events, let alone serious
ones, is low.
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